Cargando…

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future

The adoptive transfer of natural killer (NK) cells is an emerging therapy in the field of immuno-oncology. In the last 3 decades, NK cells have been utilized to harness the anti-tumor immune response in a wide range of malignancies, most notably with early evidence of efficacy in hematologic maligna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamb, Margaret G., Rangarajan, Hemalatha G., Tullius, Brian P., Lee, Dean A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992329/ https://www.ncbi.nlm.nih.gov/pubmed/33766099 http://dx.doi.org/10.1186/s13287-021-02277-x

Ejemplares similares

Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies
por: Sahin, Ugur, et al.
Publicado: (2019)

Natural Killer Cells Modulation in Hematological Malignancies
por: Baier, Céline, et al.
Publicado: (2013)

The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
por: Chu, Yaya, et al.
Publicado: (2022)

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
por: Pittari, Gianfranco, et al.
Publicado: (2015)

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies
por: Gismondi, Angela, et al.
Publicado: (2015)

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
por: Tang, Lu, et al.
Publicado: (2023)

Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
por: Giuliani, Massimo, et al.
Publicado: (2020)

Present and Future of Allogeneic Natural Killer Cell Therapy
por: Lim, Okjae, et al.
Publicado: (2015)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
por: Agasthi, Pradyumna, et al.
Publicado: (2018)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy
por: Yang, Xiao-Jing, et al.
Publicado: (2019)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

The Challenge of Targeting Notch in Hematologic Malignancies
por: Hernandez Tejada, Fiorela N., et al.
Publicado: (2014)

The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions
por: Wang, Si Chun, et al.
Publicado: (2022)

Natural killer cells in non-hematopoietic malignancies
por: Desbois, Mélanie, et al.
Publicado: (2012)

Targeting Natural Killer T Cells in Solid Malignancies
por: Ingram, Zewde, et al.
Publicado: (2021)

Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond
por: Lin, Chenyu, et al.
Publicado: (2022)

Immunotherapy in hematologic malignancies: past, present, and future
por: Im, Annie, et al.
Publicado: (2017)

Natural Killer Cell Activity Test Helps to Suspect Aggressive Natural Killer Cell Leukemia - Diagnostic Challenge
por: You, Eunkyoung, et al.
Publicado: (2023)

Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy
por: Sánchez-Ramón, Silvia, et al.
Publicado: (2016)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

COVID-19 in Hematologic Malignancies: Big Challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
por: Shaver, Kari A., et al.
Publicado: (2021)

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
por: Abedin, Sameem M, et al.
Publicado: (2016)

Role of Natural Killer Cells in HIV-Associated Malignancies
por: Leal, Fabio E., et al.
Publicado: (2017)

Natural Killer Cells in the Malignant Niche of Multiple Myeloma
por: Venglar, Ondrej, et al.
Publicado: (2022)

Liquid biopsy in hematological malignancies: current and future applications
por: Talotta, Donatella, et al.
Publicado: (2023)

Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities
por: Lloyd, Jennifer, et al.
Publicado: (2022)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Natural Killer Cell Recognition and Control of Epithelial Cancers
por: de Souza Fernandez Pereira, Marcelo, et al.
Publicado: (2022)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

Dendritic Cell Therapies for Hematologic Malignancies
por: Weinstock, Matthew, et al.
Publicado: (2017)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Natural killer cell-based therapies
por: Romagné, François, et al.
Publicado: (2011)

Allogeneic natural killer cell therapy
por: Berrien-Elliott, Melissa M., et al.
Publicado: (2023)

Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies
por: Tse, Eric, et al.
Publicado: (2022)

Engineering naturally occurring CD7(−) T cells for the immunotherapy of hematological malignancies
por: Freiwan, Abdullah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ipctsbfh5ica6ejdqeljq5cr5q